Investigators compared clinical outcomes with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel for mCRPC.

Enzalutamide may offer a survival advantage compared with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC), according to 2 US studies of older men. Overall survival ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is associated ...

ONCT-534 showed a well-tolerated safety profile in mCRPC patients on a twice-daily dosing schedule, with no grade 3 or higher toxicities reported. Despite trial discontinuation, ONCT-534 demonstrated ...

Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

(RTTNews) - Pfizer (PFE), on Thursday announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA or talazoparib in combination with XTANDI or enzalutamide for the treatment of metastatic ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...